Most recently, Kelly worked as the vice president and controller at MedImmune, and joined MedImmune as director of Sales and Marketing Finance and progressed to the role of vice president, controller.
Prior to MedImmune, Kelly worked for Biogen Idec serving in research & development finance roles of increasing responsibility, most recently as the director of Planning and Operations.
Vanda Pharma president and CEO Mihael Polymeropoulos said that they welcome Jim to Vanda and look forward to his financial leadership as they advance their late-stage product pipeline.